JNJ - Johnson & Johnson

NYSE - Nasdaq Real Time Price. Currency in USD
121.73
-0.31 (-0.25%)
As of 2:33PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close122.04
Open121.83
Bid121.79 x 800
Ask121.81 x 800
Day's Range121.13 - 122.24
52 Week Range118.62 - 148.32
Volume2,430,394
Avg. Volume6,657,029
Market Cap326.498B
Beta0.56
PE Ratio (TTM)269.31
EPS (TTM)0.45
Earnings DateJul 17, 2018
Forward Dividend & Yield3.60 (2.94%)
Ex-Dividend Date2018-05-25
1y Target Est144.45
Trade prices are not sourced from all markets
  • Cramer floats idea for 'gloomy' ETF with Wall Street's mo...
    CNBC Videos3 days ago

    Cramer floats idea for 'gloomy' ETF with Wall Street's mo...

    Jim Cramer proposes starting a new exchange-traded fund with the stocks that scare investors most when trade tensions run high.

  • Cramer floats idea for 'gloomy' ETF
    CNBC Videos3 days ago

    Cramer floats idea for 'gloomy' ETF

    Jim Cramer proposes starting a new exchange-traded fund with the stocks that scare investors most when trade tensions run high.

  • This one factor has determined which stocks rise or fall on trade-war fears
    MarketWatch2 hours ago

    This one factor has determined which stocks rise or fall on trade-war fears

    In a volatile year for the U.S. equity market, one factor has emerged as pivotal in determining whether a stock is likely to rise amid growing concerns over trade policy: how much the U.S. company focuses on the U.S.

  • Johnson & Johnson Releases Positive Study Data for Oncology Drug
    Market Realist4 hours ago

    Johnson & Johnson Releases Positive Study Data for Oncology Drug

    On June 3, Johnson & Johnson’s (JNJ) pharma subsidiary, Jannsen, released data from a Phase 2 study of erdafitinib for the treatment of patients with metastatic or unresectable urothelial carcinoma (or mUC). Johnson & Johnson presented the study results at the 2018 ASCO (American Society of Clinical Oncology) Annual Meeting, along with results for some of its other oncology drug trials, as shown in the diagram below. Jannsen’s erdafitinib, a once-daily oral pan-FGFR (fibroblast growth factor receptor) inhibitor, was designated a breakthrough therapy by the FDA in March.

  • Johnson & Johnson Receives Offer to Divest Sterilization Business
    Market Realist6 hours ago

    Johnson & Johnson Receives Offer to Divest Sterilization Business

    On June 6, Johnson & Johnson (JNJ) announced it had received a $2.8 billion offer from Fortive (FTV) to sell its ASP (Advanced Sterilization Products) business, part of its subsidiary, Ethicon. Ethicon’s ASP business, a market leader in infection prevention solutions, generated sales of $775 million in fiscal 2017. Johnson & Johnson has 120 days to decide on the offer.

  • Johnson & Johnson Accepts Sale of Its LifeScan Business
    Market Realist7 hours ago

    Johnson & Johnson Accepts Sale of Its LifeScan Business

    On June 12, Johnson & Johnson (JNJ) announced it had accepted a $2.1 billion offer for the sale of its LifeScan business, which manufactures blood glucose monitoring devices and OneTouch products, from private equity company Platinum Equity. On June 12, JNJ stock fell ~0.42% following the deal announcement.

  • How Johnson & Johnson’s Valuation Compares
    Market Realist23 hours ago

    How Johnson & Johnson’s Valuation Compares

    Johnson & Johnson (JNJ), one of the world’s largest healthcare companies, has a diversified business spanning its consumer, medical device, and pharmaceutical segments. The company reported sales of $20 billion in Q1 2018 and adjusted EPS of $2.06. Let’s look at Johnson & Johnson’s valuation metrics.

  • A Look at Johnson & Johnson’s Stock Performance
    Market Realistyesterday

    A Look at Johnson & Johnson’s Stock Performance

    Johnson & Johnson (JNJ) closed June 18 at $121.30 per share. The stock reached a 52-week low of $118.60 on May 29 as the company scrapped a Phase 1b/2 trial for its drug, Darzalex, for the treatment of advanced or metastatic non-small cell lung cancer patients, in combination with Roche’s (RHHBY) Tecentriq. Since then, the stock has risen ~1.6%.

  • What Analysts Recommend for Johnson & Johnson Stock
    Market Realistyesterday

    What Analysts Recommend for Johnson & Johnson Stock

    Johnson & Johnson (JNJ) is one of the biggest healthcare players in the world. However, it has been impacted by growing competition and pricing pressure in the industry in recent years and has revised its strategy. The company has witnessed recuperating sales in its medical devices business along with improving dynamics in its consumer business, which has encountered some litigation recently. The company’s pharmaceuticals business has performed steadily, with key trial data being announced. Let’s look at analysts’ recommendations for JNJ stock.

  • A Look at Allergan’s Valuation as of June 19
    Market Realistyesterday

    A Look at Allergan’s Valuation as of June 19

    Allergan (AGN), a leading specialty pharmaceutical company, is focused on developing, manufacturing, and commercializing pharmaceutical and biologic products.

  • Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks
    Motley Foolyesterday

    Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks

    J&J's dividend is good. But these are even better.

  • Here’s how much Houston public companies spent on litigation in 2017
    American City Business Journalsyesterday

    Here’s how much Houston public companies spent on litigation in 2017

    Meanwhile, the nation’s largest banks are preparing for a timeout from the courtroom following years of being pummeled by shareholder and investor lawsuits in the wake of the Great Recession.

  • What’s the Latest on Teva’s Fremanezumab?
    Market Realist2 days ago

    What’s the Latest on Teva’s Fremanezumab?

    Teva’s (TEVA) much-awaited migraine drug, Fremanezumab, is in late-stage trials for the treatment of cluster headaches. The company provided an update regarding its Enforce Phase III clinical development program for the treatment of cluster headaches on June 15.

  • TheStreet.com2 days ago

    The Charts and Indicators on Johnson & Johnson Are Still Mostly Bearish

    is another company that Jim Cramer put in his new GLOOM index last night on his Mad Money show on CNBC. In this updated daily bar chart of JNJ, below, we have more bearish signals than bullish ones. JNJ broke down below the rising 50-day moving average line in late January and the slope of the line quickly turned negative.

  • Bloomberg2 days ago

    Opioid Ruling Could Send  Purdue, Drugmakers to Court

    Purdue Pharma LP, Johnson & Johnson and other opioid makers faced one of the first extensive review of their legal defenses to state claims that they violated consumer-protection laws and created a public nuisance with the sale of the pain killers. New York state court Judge Jerry Garguilo on Monday rejected the pharma companies’ requests for the lawsuits be thrown out on a myriad of grounds, concluding lawyers for eight counties could move forward with their claims. While the ruling is based solely on New York law, it could provide a roadmap for other judges around the U.S. weighing whether states and local governments can proceed with claims that Purdue and other opioid makers understated the risks of prescription opioids and overstated their benefits.

  • Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
    PR Newswire2 days ago

    Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

    NEW BRUNSWICK, N.J., June 19, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 17, to review second-quarter results.  Alex Gorsky, Chairman and Chief Executive Officer and Joseph J. Wolk, Executive Vice President, Chief Financial Officer will host the call. The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.

  • 3 Stocks That Are Absurdly Cheap Right Now
    Motley Fool2 days ago

    3 Stocks That Are Absurdly Cheap Right Now

    When stocks become nonsensically priced due to irrational market decisions, investors should act on the opportunity.

  • Reuters2 days ago

    FOCUS-After split from Actelion, Idorsia CEO plans to raise more cash in 2019

    Swiss biotech Idorsia, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson, will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters. French founders Jean-Paul Clozel and his wife, Martine Clozel, sold Actelion for $30 billion last year, but only after extracting rights to 11 prized drugs in development, including an insomnia medicine nicknamed DORA.

  • Markets Right Now: Stocks look to recover from early skid
    Associated Press3 days ago

    Markets Right Now: Stocks look to recover from early skid

    NEW YORK (AP) — The latest on developments in financial markets (all times local):

  • TheStreet.com3 days ago

    3 Great Stocks for Retirees to Own

    Congratulations! You've just retired. Investors and financial planners both suggest that dividend stocks can be a great source of income for those looking to supplement their retirement savings. The blue-chip stock's staying power and brand recognition should be viewed favorably by retiree investors, says Robert Johnson, principal at the Fed Policy Investment Research Group.

  • Reuters3 days ago

    After split from Actelion, Idorsia CEO plans to raise more cash in 2019

    Swiss biotech Idorsia, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson, will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters. French founders Jean-Paul Clozel and his wife, Martine Clozel, sold Actelion for $30 billion last year, but only after extracting rights to 11 prized drugs in development, including an insomnia medicine nicknamed DORA. With 650 employees, Jean-Paul Clozel expects to burn through Idorsia's cash in about two years, before his drug hopefuls generate revenue - typical of the biotech industry where the risk of pipeline failures is ever-present but the rewards of striking paydirt, as was the case with Actelion, can be vast.

  • Why Geron Corporation Stock Is Heading Higher Today
    Motley Fool3 days ago

    Why Geron Corporation Stock Is Heading Higher Today

    The company's EHA conference over the weekend has investors snapping up shares today.

  • PR Newswire3 days ago

    FDA Approves the Next Generation of Customized LASIK Treatment with iDESIGN Refractive Studio

    Next generation LASIK platform that measures the eye inside and out to enable highly precise personalized vision correction Only available LASIK platform indicated for monovision LASIK in presbyopic myopic ...

  • UNF, Mayo experiment with rare 3-D microscope
    American City Business Journals3 days ago

    UNF, Mayo experiment with rare 3-D microscope

    The University of North Florida is temporarily housing a highly advanced microscope, the only one of its kind in North America.

  • Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming
    Motley Fool4 days ago

    Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming

    Several big pharma companies are about to lose patent exclusivity for blockbuster drugs. Should investors be worried?